Takeda Drug Achieves Primary Endpoint of Clinical Remission in Moderately to Severely Active Ulcerative Colitis

Takeda Drug Achieves Primary Endpoint of Clinical Remission in Moderately to Severely Active Ulcerative Colitis

Source: 
CP Wire
snippet: 
  • A statistically significant proportion of patients achieved clinical remission at week 52 compared to placebo
  • Vedolizumab is a humanized monoclonal antibody specifically designed to mediate inflammation in UC and CD patients
  • In a previous study, Vedolizumab, achieved superior results in mucosal healing vs TNFα-antagonist therapy